| 5.1 Infection |
25 |
4101 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.96, 1.15] |
| 5.1.1 Dexamethasone |
18 |
2821 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.91, 1.15] |
| 5.1.2 Hydrocortisone |
7 |
1280 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.94, 1.25] |
| 5.2 Hyperglycaemia |
14 |
2688 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [1.15, 1.37] |
| 5.2.1 Dexamethasone |
12 |
2117 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.35 [1.21, 1.49] |
| 5.2.2 Hydrocortisone |
2 |
571 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.84, 1.22] |
| 5.3 Hypertension |
11 |
1993 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.85 [1.54, 2.22] |
| 5.3.1 Dexamethasone |
10 |
1943 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.84 [1.53, 2.21] |
| 5.3.2 Hydrocortisone |
1 |
50 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.33, 26.92] |
| 5.4 Hypertrophic cardiomyopathy |
1 |
50 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.33 [1.40, 13.37] |
| 5.5 Growth failure |
1 |
50 |
Risk Ratio (M‐H, Fixed, 95% CI) |
6.67 [2.27, 19.62] |
| 5.6 Pulmonary air leak |
17 |
3276 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.73, 1.11] |
| 5.6.1 Dexamethasone |
12 |
2041 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.66, 1.08] |
| 5.6.2 Hydrocortisone |
5 |
1235 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.72, 1.56] |
| 5.7 Patent ductus arteriosus (PDA) |
24 |
4013 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.78 [0.72, 0.85] |
| 5.7.1 Dexamethasone |
17 |
2706 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.69, 0.84] |
| 5.7.2 Hydrocortisone |
7 |
1307 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.71, 0.95] |
| 5.8 Severe IVH |
26 |
4103 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.84, 1.12] |
| 5.8.1 Dexamethasone |
17 |
2736 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.81, 1.14] |
| 5.8.2 Hydrocortisone |
9 |
1367 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.76, 1.27] |
| 5.9 Severe intraventricular haemorrhage (IVH) in infants examined |
8 |
1964 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.75, 1.12] |
| 5.9.1 Dexamethasone |
4 |
994 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.78 [0.59, 1.03] |
| 5.9.2 Hydrocortisone |
4 |
970 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.11 [0.82, 1.49] |
| 5.10 Periventricular leukomalacia (PVL) |
15 |
2807 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.83, 1.53] |
| 5.10.1 Dexamethasone |
8 |
1514 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [0.84, 1.81] |
| 5.10.2 Hydrocortisone |
7 |
1293 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.58, 1.59] |
| 5.11 PVL in infants with cranial ultrasound scans |
7 |
1841 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.79, 1.60] |
| 5.12 PVL in survivors seen at follow‐up |
2 |
183 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.22 [0.60, 2.48] |
| 5.13 Necrotising enterocolitis (NEC) |
25 |
4050 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.74, 1.11] |
| 5.13.1 Dexamethasone |
15 |
2661 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.69, 1.13] |
| 5.13.2 Hydrocortisone |
10 |
1389 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.66, 1.37] |
| 5.14 Gastrointestinal bleeding |
12 |
1816 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.86 [1.35, 2.55] |
| 5.14.1 Dexamethasone |
10 |
1725 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.87 [1.35, 2.58] |
| 5.14.2 Hydrocortisone |
2 |
91 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.53 [0.27, 8.74] |
| 5.15 Gastrointestinal perforation |
16 |
3040 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.84 [1.36, 2.49] |
| 5.15.1 Dexamethasone |
9 |
1936 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.73 [1.20, 2.51] |
| 5.15.2 Hydrocortisone |
7 |
1104 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.05 [1.21, 3.47] |
| 5.16 Pulmonary haemorrhage |
10 |
1820 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.16 [0.87, 1.54] |
| 5.16.1 Dexamethasone |
7 |
686 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.65, 1.45] |
| 5.16.2 Hydrocortisone |
3 |
1134 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.36 [0.92, 2.03] |
| 5.17 Any retinopathy of prematurity (ROP) |
9 |
1345 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.80, 0.97] |
| 5.17.1 Dexamethasone |
8 |
1042 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.72, 0.99] |
| 5.17.2 Hydrocortisone |
1 |
303 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.84, 1.04] |
| 5.18 Severe ROP |
14 |
2577 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.67, 0.99] |
| 5.18.1 Dexamethasone |
8 |
1507 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.77 [0.60, 0.99] |
| 5.18.2 Hydrocortisone |
6 |
1070 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.65, 1.23] |
| 5.19 Severe ROP in survivors |
12 |
1575 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.77 [0.64, 0.94] |
| 5.19.1 Dexamethasone |
10 |
1238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.59, 0.95] |
| 5.19.2 Hydrocortisone |
2 |
337 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.60, 1.17] |
